Dapsone – USA

Dapsone – USA

IPR decision: Aug. 27, 2019

AIA Review
Filing Date
Institution Date
Petitioner
US Patent
Respondent
Final Decision
IPR2018-00608
02/12/2018
08/29/2018
Amneal Pharma. LLC
9,161,926
Allergan, Inc.
Claims 1–6 are patentable
US 9,161,926 (Allergan, Inc.; Exp: 11/18/2033) – listed in OB

1. A topical pharmaceutical composition comprising: about 7.5% w/w dapsone; about 30% w/w to about 40% w/w diethylene glycol monoethyl ether; about 2% w/w to about 6% w/w of a polymeric viscosity builder consisting of acrylamide/sodium acryloyldimethyl taurate copolymer; and water; wherein the composition does not comprise adapalene.

5. A topical pharmaceutical composition comprising: about 7.5% w/w dapsone; about 30% w/w diethylene glycol monoethyl ether; about 4% w/w of a polymeric viscosity builder consisting of acrylamide/sodium acryloyldimethyl taurate copolymer; and water; wherein the composition does not comprise adapalene.

Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved